Bone-Remodeling Factor Balance and Osteoporosis Molecular Pattern



- **Osteoporosis is the most common type of bone disease worldwide, involving low bone mineral density and increased susceptibility to fracture. More than 200 million people worldwide (30% of women and 20% of men over 50) suffer from osteoporosis or osteoporotic fractures.**
- **Osteoporosis is associated with postmenopausal period but it is also a major comorbidity in obesity, type 2 diabetes mellitus, chronic obstructive pulmonary disease, systemic lupus erythematosus and has strong genetic determination (60% heritability), and over 100 genes and proteins are underlying osteoporosis and influencing the response to anti-osteoporotic therapy.**
- **We customize an effective assessment of osteoporosis and fracture risk, and monitoring of anti-osteoporosis treatment efficacy, supported by a Laboratory Diagnostic Test (LDT) using a protein expression profiling method based on a multiplex fully automated, protein array chip system.**
- **Our LDT determines the blood level of a broad number of bone turnover and inflammatory biomarkers including sclerostin (SOST), osteocalcin (OSC), osteoprotegerin (OPG), secreted frizzled related protein 1 (SFRP-1), Dickkopf 1 (DKK-1), IGF-1, osteopontin (OPN), C-telopeptide type I collagen (β-CTX), N-terminal procollagen prepeptide (P1NP), receptor activator nuclear κB ligand (RANKL), tumor necrosis factor alpha (TNFa), C-reactive protein (hsCRP), vitamin D3 (1,25-dihydroxycholecalciferol) and parathyroid hormone (PTH).**

PERSONA BIOMED Inc. is a clinical-stage biotech company devoted to the development of clinically-validated gene and molecular expression profiling methods for contributing to the success of Precision Medicine.

Contact Information: Persona Biomed, Inc. 625 N. Washington St., Suite 425 Alexandria, VA 22314
personabiomed@gmail.com; www.personabiomed.com